Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Beyond Reference Management: How Literature Management is a Win for the Life Science Organization

Posted on April 7th, 2021 by

Pharma R&D

Scientific literature is a critical component to virtually all aspects of a life science enterprise, including Medical Affairs, Pharmacovigilance and R&D. However, the process of curating and sharing literature can lead to significant challenges in organizing content, facilitating collaboration and enforcing copyright compliance.

(more…)

COVID-19 Treatment Trial Reaches Out to Communities of Color

Posted on April 5th, 2021 by

COVID-19

An ongoing problem in clinical trials over the years has been a failure to procure diverse enough representation among the participants. For a long time, this was due to bias and oversight on the part of the research community, and the consequence was a lack of full understanding in how medications and treatments affected women and various racial/ethnic minorities.

(more…)

phactMI: Delivering accurate drug information to point of care, part II

Posted on March 31st, 2021 by

Medical Information

Part 2: The challenges that can restrict access to the latest and most accurate information on medications

Healthcare professionals are the ones tasked with safely prescribing, dispensing and managing medications. As mentioned in part 1 of this series, that puts them in the position of needing to know — or being able to quickly check — the latest information about a huge number of new and existing medical products.

(more…)

FDA Introduces Data Modernization Action Plan

Posted on March 29th, 2021 by

Pharma R&D

One of the frustrations of our Big Data era is that, despite the existence of an ever-growing wealth of valuable data, this data is often stuck in different silos. This lack of accessibility makes it hard to get the most out of data that has the potential to be extremely useful.

(more…)

Harris Poll Finds Large Boost in Pharma Industry Reputation

Posted on March 15th, 2021 by

Pharma R&D

As the COVID-19 vaccine roll-out gains in intensity, it has become common to hear people toss out the names of pharmaceutical companies like Pfizer, Moderna and AstraZeneca with the same ease that they refer to their favorite brands of ketchup or peanut butter. This isn’t typical. While direct-to-consumer advertising has perhaps increased some awareness of drug makers, the pandemic has made pharma R&D a subject of public interest in an unprecedented fashion.

(more…)

phactMI: Delivering accurate drug information to point of care

Posted on March 2nd, 2021 by

Medical Information

Part 1: How healthcare professionals can access the latest and most accurate information on medications

Access to accurate, up-to-date information on medications helps healthcare professionals make better decisions. Before prescribing or dispensing a drug, it’s essential to have some insight into its behaviors — desired effect, required storage conditions, potential off-target effects, drug–drug interactions and so on. Physicians, nurse practitioners and pharmacy staff members demonstrate an incredible knowledge of drugs, built up through many years of point-of-care experience. This knowledge informs their clinical decisions.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 83

About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.